Schwieger Lara, Switchenko Jeffrey M, Cao Yichun, Amaniera Isabella, Phillips-Reed Rogsbert, Godette Karen, Rizzo Monica
Emory School of Medicine, Atlanta, Georgia, USA.
Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Atlanta, Georgia, USA.
J Surg Oncol. 2024 Oct;130(5):997-1005. doi: 10.1002/jso.27814. Epub 2024 Aug 29.
BACKGROUND: Intraoperative radiotherapy (IORT) offers more convenience compared to external beam radiotherapy (EBRT) following breast-conserving surgery for early-stage breast cancer. This study describes the implementation of IORT at a metropolitan academic cancer center. METHODS: Demographics, tumor characteristics, margin status, adjunct EBRT, and cosmetic results were retrospectively analyzed in patients undergoing BCS with IORT. IORT consists of 20 gray delivered to the partial mastectomy cavity. RESULTS: From 2015 to 2020, 171 patients (65.5% African American) were included. Histologically, 104 (60.8%) patients had invasive ductal carcinoma (IDC), while 67 (39%) patients had DCIS only. Seventeen (15.9%) patients with IDC and 12 (8.6%) patients with DCIS had positive margins. There were 15 ipsilateral breast recurrences (8.8%) and three patients (20%) developed systemic disease. Twenty-five patients (14.6%) underwent adjuvant EBRT. The local recurrence-free survival at 60 months from date of IORT was 89.4% (95% CI 82.7%-93.6%). For overall survival (OS), 168 (98.2%) patients were alive at a median follow-up of 51.4 months, and three total deaths were recorded. CONCLUSIONS: IORT is a highly desirable and convenient alternative to EBRT for early-stage breast cancer especially for patients with poor compliance. IORT has an acceptable ipsilateral recurrence while not precluding adjunct EBRT based upon the final pathologic report.
背景:对于早期乳腺癌保乳手术后的患者,术中放疗(IORT)相比外照射放疗(EBRT)更为便捷。本研究描述了一家大都市学术癌症中心开展IORT的情况。 方法:对接受保乳手术联合IORT的患者的人口统计学特征、肿瘤特征、切缘状态、辅助性EBRT及美容效果进行回顾性分析。IORT包括对部分乳房切除腔给予20格雷的剂量。 结果:2015年至2020年,纳入了171例患者(65.5%为非裔美国人)。组织学上,104例(60.8%)患者患有浸润性导管癌(IDC),而67例(39%)患者仅患有导管原位癌(DCIS)。17例(15.9%)IDC患者和12例(8.6%)DCIS患者切缘阳性。有15例(8.8%)同侧乳房复发,3例(20%)患者出现全身性疾病。25例(14.6%)患者接受了辅助性EBRT。从IORT日期起60个月时的局部无复发生存率为89.4%(95%CI 82.7%-93.6%)。对于总生存期(OS),在中位随访51.4个月时,168例(98.2%)患者存活,记录到3例死亡。 结论:对于早期乳腺癌,尤其是依从性差的患者,IORT是一种非常理想且便捷的EBRT替代方案。IORT的同侧复发率可接受,同时不排除根据最终病理报告进行辅助性EBRT。
J Surg Oncol. 2024-10